KDventures AB Share Price

KDV B

SE0002190926

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Stockholm Other stock markets 17:00:00 24/07/2026 BST			5-day change	1st Jan Change
0.2465 ^SEK	-0.20%		+0.41%	-43.46%

07-09	KD Ventures portfolio company PharmNovo raises SEK 39m	FW
06-25	KDventures: Anacardio's heart failure study published in The Lancet	FW

Analysts' recommendations: KDventures AB

05-11	Redeye: KD Ventures trading at a steep discount to NAV	FW
05-11	Redeye initiates coverage of KD Ventures with a fair value of SEK 1.0 per share	FW
11-17	DNB Carnegie Lowers Target Value for Karolinska Development to SEK 1.4-2.1 per Share	FW
11-04	Karolinska Development's Modus Therapeutics gets approval for 2nd part of phase 2 study	RE
11-04	Modus Therapeutics Receives Approval for Second Part of Phase 2 Study in Chronic Kidney Disease with anemia	CI

More recommendations

Managers and Directors: KDventures AB

Manager	Title	Age	Since
Viktor Drvota CEO	Chief Executive Officer	61	31/05/2017
Hans Christopher Toll DFI	Director of Finance/CFO	58	30/09/2022
Mikaela Sörman CIO	Chief Investment Officer	-	-

Director	Title	Age	Since
Theresa Y. Y. Tse BRD	Director/Board Member	33	27/11/2017
Anna Lefevre Skjöldebrand BRD	Director/Board Member	57	18/02/2021
Benjamin Toogood CHM	Chairman	50	17/12/2024

More insiders

Other Medical Equipment, Supplies & Distribution

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
KDVENTURES AB	-0.20%	+0.41%	-74.90%	-84.88%	16.67M
ABBOTT LABORATORIES	+2.29%	+4.28%	-18.10%	-9.83%	175B
MEDTRONIC PLC	+1.46%	-0.42%	-9.56%	-6.46%	105B
CENCORA, INC.	+1.58%	+0.62%	+5.61%	+60.91%	59.35B
HOYA CORPORATION	-1.13%	-1.96%	+32.11%	+56.38%	50.71B
BECTON, DICKINSON AND COMPANY	+2.22%	-2.23%	-14.36%	-40.96%	42.15B
MEDLINE INC.	+2.98%	-5.74%	-	-	31.82B
DEXCOM, INC.	+1.50%	-8.26%	-17.23%	-45.22%	27.2B
WEST PHARMACEUTICAL SERVICES, INC.	-7.67%	-9.45%	+44.38%	-13.02%	25.11B
STERIS PLC	+1.63%	-3.19%	-5.06%	-7.76%	20.53B
Average	+0.33%	-3.02%	-6.34%	-10.09%	53.73B
Weighted average by Cap.	+0.97%	-1.51%	-4.52%	+1.24%

See all sector performances

Karolinska Development AB is a Sweden-based investment company. The Company provides capital to biotechnology firms, as well as develops and commercializes biotechnological products. Its activities are involved in a range of areas: oncology, infections and wound healing, womenâ€™s health, cardiovascular and hematology, medical equipment, diagnostics, pharmaceutical formulation, as well as implants, among others. The Companyâ€™s pharmaceuticals portfolio comprises: AXL1717 for non-small-cell lung carcinoma (NSCLC), APR-246 for ovarian cancer, Sevuparin for malaria, SHACT for pain relief at hysteroscopy and intrauterine device (IUD) insertion, and PC-mAB for acute coronary syndrome (ACS), among others. Furthermore, the Company controls a number of subsidiaries, such as Avaris AB, HBV Thernostica AB, KD Incentive AB, KDev Oncology AB and Limone AB.

Employees

Sector

Medical Equipment, Supplies & Distribution

Calendar

08-26 Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
24/07/26	SEK 0.2465	-0.20%	325,289
23/07/26	SEK 0.2470	+0.41%	351,628
22/07/26	SEK 0.2460	+1.23%	277,735
21/07/26	SEK 0.2430	0.00%	604,114
20/07/26	SEK 0.2430	-1.02%	423,137

Delayed Quote Nasdaq Stockholm

More quotes

Income Statement and Estimates

More financial data

Annual profits - Rate of surprise

Company calendar

Market Cap	163M 16.73M 14.71M 13.68M 12.55M 23.58M 1.62B 23.97M 63.67M 792M 62.82M 61.46M 2.76B	P/E 2024	-31.7x	P/E 2025	-0.61x
Enterprise Value	140M 14.39M 12.65M 11.76M 10.79M 20.28M 1.39B 20.61M 54.74M 681M 54M 52.84M 2.38B	EV / Sales 2024	118x	EV / Sales 2025	56.8x
Free-Float	65.1%	Yield 2024 *	-	Yield 2025	-

07-09	KDventures' : portfolio company PharmNovo secures capital ahead of phase 2 study; holding written down	PU
07-09	KDventures’ portfolio company PharmNovo secures capital ahead of phase 2 study; holding written down	AQ
06-30	Change of number of shares and votes in KDventures AB	AQ
06-25	KDventures' : portfolio company AnaCardio's clinical study of drug candidate AC01 published in The Lancet	PU
06-25	KDventures’ portfolio company AnaCardio’s clinical study of drug candidate AC01 published in The Lancet	AQ

1 day	-0.20%
1 week	+0.41%
Current month	+1.44%
1 month	-2.38%
3 months	-14.71%
6 months	-18.24%
Current year	-43.46%

1 week	0.24	0.25
1 month	0.24	0.27
Current year	0.2	0.45
1 year	0.2	1.24
3 years	0.2	1.95
5 years	0.2	11.24
10 years	0.2	11.24

Date	Insider	Type	Main position	Quantity	% Market Cap.
27/03/23	Johan Dighed	Buy	General Counsel	50,000	0.0187%
30/09/22	Johan Dighed	Buy	General Counsel	40,187	0.0150%
08/03/22	Benjamin Toogood	Buy	Chairman	64,001	0.0367%

KDventures AB Share Price

Stocks

KDV B

SE0002190926

Medical Equipment, Supplies & Distribution

Valuation: KDventures AB

Chart: KDventures AB

Latest news : KDventures AB

Analysts' recommendations: KDventures AB

Press Releases: KDventures AB

Quotes and Performance

Course Extremes

Managers and Directors: KDventures AB

Latest insider transactions

Other Medical Equipment, Supplies & Distribution

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

	2024	2025
Net sales	1.84M 189K 166K 155K 142K 267K 18.27M 271K 720K 8.95M 710K 695K 31.25M	1.67M 172K 151K 141K 129K 242K 16.61M 246K 655K 8.14M 646K 632K 28.41M
Net income	-8.1M -834K -733K -682K -626K -1.18M -80.54M -1.19M -3.17M -39.46M -3.13M -3.06M -138M	-194M -19.96M -17.55M -16.32M -14.98M -28.13M -1.93B -28.59M -75.95M -944M -74.93M -73.31M -3.3B
Net Debt	-39.9M -4.11M -3.61M -3.36M -3.08M -5.79M -397M -5.88M -15.63M -194M -15.42M -15.09M -678M	-22.8M -2.35M -2.06M -1.92M -1.76M -3.31M -227M -3.36M -8.93M -111M -8.81M -8.62M -388M